Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 639-646, December 2008

Are new agents really making a difference in MDS?

  • Richard M. Stone, MD (Associate Professor of Medicine, Harvard Medical School Director, Adult Leukemia Program)

      Affiliations

    • Corresponding Author InformationAdult Leukemia Program, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. Tel.: +1 617 632 2214; Fax: +1 617 632 2933.

Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA

Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow stem cell disorders characterized by dysplastic hypercellular marrows with peripheral cytopenias. The Leukemia & Lymphoma Society estimates the annual US incidence of MDS is at least 12,000. MDS occurs primarily in people over 60 years old. The pathophysiology of most subtypes of MDS is poorly understood. Treating MDS remains a challenge despite the availability of new agents, such as lenalidomide, azacitidine, and decitabine. Whether these drugs have made a real difference in treating this group of diseases remains controversial.

Key words: myelodysplastic syndromes, lenalidomide, azacitidine, decitabine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(08)00055-8

doi:10.1016/j.beha.2008.06.004

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 639-646, December 2008

Article Tools